戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  to inform decisions on withholding adjuvant systemic chemotherapy.
2 rnally-cooled electrodes in association with systemic chemotherapy.
3 matic disease sites as well as intra-CSF and systemic chemotherapy.
4 matic disease sites as well as intra-CSF and systemic chemotherapy.
5 anced pancreatic NETs after failure of prior systemic chemotherapy.
6 f patients are spared the adverse effects of systemic chemotherapy.
7  and radiographic complete remission (CR) to systemic chemotherapy.
8 laced by intensive intrathecal treatment and systemic chemotherapy.
9  reduction in febrile neutropenia (FN) after systemic chemotherapy.
10 prove the selection of patients for adjuvant systemic chemotherapy.
11 umoral injections of rF-mCD40L together with systemic chemotherapy.
12 e patients, the asymptomatic BM responded to systemic chemotherapy.
13  (at diagnosis of SCLC) and after first-line systemic chemotherapy.
14  small-cell lung cancer (SCLC) to first-line systemic chemotherapy.
15 ed therapy with cystectomy and perioperative systemic chemotherapy.
16 d less than a quarter of patients respond to systemic chemotherapy.
17 on, given the improvement in the efficacy of systemic chemotherapy.
18 ume of the brain and spine), with or without systemic chemotherapy.
19 ntriculoatrial shunts, prior craniotomy, and systemic chemotherapy.
20 agent in NSCLC should be in combination with systemic chemotherapy.
21 ents who underwent surgery and postoperative systemic chemotherapy.
22 long-term cognitive deficits associated with systemic chemotherapy.
23  who received both surgery and postoperative systemic chemotherapy.
24 asome inhibition as an important adjuvant to systemic chemotherapy.
25 irty-three patients (75%) had received prior systemic chemotherapy.
26 sed patient with HCC had previously received systemic chemotherapy.
27 lized disease, (2) interferon-alpha, and (3) systemic chemotherapy.
28 primary site; more recently, it has included systemic chemotherapy.
29 ents had progressive disease following prior systemic chemotherapy.
30 chemotherapy and two more cycles of the same systemic chemotherapy.
31 up C, development of brain metastases during systemic chemotherapy.
32  volumes to higher doses in conjunction with systemic chemotherapy.
33 atment that includes surgery, radiation, and systemic chemotherapy.
34  tempered by altering the dosing schedule of systemic chemotherapy.
35 ed efficacy and reduced toxicity compared to systemic chemotherapy.
36 apeutic concentration at the tumor site with systemic chemotherapy.
37 ients with the goal of providing time off of systemic chemotherapy.
38  metastases in patients receiving first-line systemic chemotherapy.
39 who received HAI also received perioperative systemic chemotherapy.
40 as shown multifarious advantages compared to systemic chemotherapy.
41 r patients with TRIL who have received prior systemic chemotherapy.
42  disease, implications for surveillance, and systemic chemotherapy.
43 ecific likelihood of receiving postoperative systemic chemotherapy.
44              A total of 40 patients received systemic chemotherapy.
45 redict the response of human lung cancers to systemic chemotherapy.
46 ant chemotherapy also received postoperative systemic chemotherapy.
47 ents, despite the administration of adjuvant systemic chemotherapy.
48 ression reduction (IR) followed by immediate systemic chemotherapy.
49 ersus >/= 25%); 2) prior platinum-containing systemic chemotherapy; 3) embolization of segments 5-8 v
50                                      Initial systemic chemotherapy (6 months) with a combination regi
51                        Adding RF ablation to systemic chemotherapy achieved local control in a large
52  Postoperative HAI oxaliplatin combined with systemic chemotherapy after curatively intended surgery
53            Preoperative therapy consisted of systemic chemotherapy alone (n = 38; 6.5%), chemoradiati
54 125 consecutive patients who received modern systemic chemotherapy alone after liver resection.
55                      Patients who have CR to systemic chemotherapy alone can achieve impressive survi
56 T FINDINGS: Improved prognosis compared with systemic chemotherapy alone has recently been demonstrat
57    Factors associated with achieving CR with systemic chemotherapy alone included FOLFOX4 treatment,
58                                              Systemic chemotherapy alone resulted in only transient t
59  and intraperitoneal chemotherapy (IPC) over systemic chemotherapy alone, the treatment of peritoneal
60  with improved survival compared to adjuvant systemic chemotherapy alone.
61 tic recurrence compared with adjuvant modern systemic chemotherapy alone.
62 percent in the group treated with local plus systemic chemotherapy and 72 percent in the group given
63 treatment of the CNS included both high-dose systemic chemotherapy and intrathecal therapy, in contra
64      Supporting evidence for the paradigm of systemic chemotherapy and intratumoral administration of
65 ents who had failed to respond adequately to systemic chemotherapy and local treatment where appropri
66 sis of PVRL relative to the use or nonuse of systemic chemotherapy and other treatment regimens.
67 therapy were randomized to receive intensive systemic chemotherapy and presymptomatic CNS therapy tha
68                           Treatment includes systemic chemotherapy and radiation with current regimen
69 ciation was independent of the use of modern systemic chemotherapy and remained in propensity score a
70 ced non-small cell lung cancer has been with systemic chemotherapy and usually consists of a platinum
71 tes of extracranial disease who failed early systemic chemotherapy and were able to receive SBRT and
72 ease metastatic to the brain is curable with systemic chemotherapy and whole-brain irradiation.
73             All patients received multiagent systemic chemotherapy and whole-brain irradiation.
74  to relieve pain when used concurrently with systemic chemotherapy and/or hormonal therapy, since it
75 patients enrolled, 117 had received no prior systemic chemotherapy, and 34 had received prior chemoth
76  and antibody therapies such as alemtuzumab, systemic chemotherapy, and allogeneic transplantation.
77 ternal beam radiotherapy, reduced the use of systemic chemotherapy, and diminished enucleations by 90
78 rs for OS included adenocarcinoma histology, systemic chemotherapy, and no IP therapy.
79  for 55 patients: 39 patients (78%) received systemic chemotherapy, and of the 16 patients (28%) who
80 bidities, and treatment modalities including systemic chemotherapy, antiangiogenic therapy, and hospi
81                        Although the standard systemic chemotherapy approaches are emerging, the progn
82 ths and current therapeutic options, such as systemic chemotherapy, are often ineffective.
83                                              Systemic chemotherapy arrested the decline in visual acu
84 e to target these pathways concurrently with systemic chemotherapy as a strategy to improve the clini
85 er received significantly more postoperative systemic chemotherapy at all stages, but they experience
86                                   The use of systemic chemotherapy before definitive locoregional man
87              Seventy patients (89%) received systemic chemotherapy before RT.
88 cancer or lymphoma who had been treated with systemic chemotherapy (breast, n = 141, age = 57.0 +/- 1
89              Brain tumors are protected from systemic chemotherapy by the blood-brain barrier (BBB) a
90 e the risk of subsequent metastatic disease, systemic chemotherapy can be introduced early during the
91  from this study support the hypothesis that systemic chemotherapy can have a negative impact on cogn
92 l injection of CpG oligodeoxynucleotide plus systemic chemotherapy can induce a T-cell immune respons
93 ase II trials have demonstrated tolerance to systemic chemotherapy; chemotherapy plus radiation prior
94 oma even in localized disease whereas IR and systemic chemotherapy (CHOP-21) could achieve lasting co
95 nal Cancer Data Base who received multiagent systemic chemotherapy combined with high-intensity versu
96 8 times more likely to receive postoperative systemic chemotherapy compared with older patients (65-7
97                  Strikingly, the addition of systemic chemotherapy (cyclophosphamide) combined with l
98  of patients and fewer patients who received systemic chemotherapy developed pineoblastoma, possibly
99                The addition of postoperative systemic chemotherapy did not result in matched survival
100 l mucin debulking, adenocarcinoma histology, systemic chemotherapy, diffuse IP disease at presentatio
101 option for patients who did not receive full systemic chemotherapy doses during radiotherapy.
102 otrexate, as well as the roles of additional systemic chemotherapy drugs, intrathecal therapy, and cr
103  to inform decisions on withholding adjuvant systemic chemotherapy due to its ability to identify a g
104  treated with OAC after prior treatment with systemic chemotherapy, external beam radiation, or both
105 ents received two cycles of bolus 5-FU-based systemic chemotherapy followed by pelvic radiation thera
106                  The preferred algorithm was systemic chemotherapy, followed by liver resection, then
107                                              Systemic chemotherapies for various malignancies have be
108         Peripheral neuropathy symptoms after systemic chemotherapy for breast cancer are associated w
109  combined intratumoral injections of DCs and systemic chemotherapy for cancer treatment.
110 he dilemma of whether or not to give/receive systemic chemotherapy for CRC.
111                     Despite recent advances, systemic chemotherapy for metastatic disease without the
112                                              Systemic chemotherapy for operable breast cancer substan
113  with an improved survival, as compared with systemic chemotherapy for peritoneal carcinomatosis from
114 after sequential thermal laser combined with systemic chemotherapy for retinoblastoma.
115                                  The role of systemic chemotherapy for soft-tissue sarcoma is still e
116                      The survival benefit of systemic chemotherapy for the treatment of liver cancer
117                    The role of perioperative systemic chemotherapy for this particular metastatic dis
118                                              Systemic chemotherapy generally has been considered immu
119  univariate analysis, the use of neoadjuvant systemic chemotherapy had a significant positive prognos
120                      Response to neoadjuvant systemic chemotherapy had no significant prognostic impa
121                                              Systemic chemotherapy has improved the survival of patie
122                                              Systemic chemotherapies have been shown to improve clini
123           Although definitive data regarding systemic chemotherapy in adjuvant therapy are scarce, th
124 cancer (CRC) can be rendered resectable with systemic chemotherapy in approximately 20% of cases.
125 rove survival, advances have been made using systemic chemotherapy in both the perioperative settings
126 h IT mafosfamide administered with intensive systemic chemotherapy in children younger than 3 years w
127 Evidence supports the safety and efficacy of systemic chemotherapy in fit older patients motivated en
128 mersen sodium) could improve the efficacy of systemic chemotherapy in patients with advanced melanoma
129              First reports using neoadjuvant systemic chemotherapy in patients with unresectable dise
130 s with a PS of 2 (PS2); thus, the benefit of systemic chemotherapy in PS2 patients is uncertain.
131                                  The role of systemic chemotherapy in the management of pancreatic en
132 erial chemoembolization and/or perioperative systemic chemotherapy in the treatment of advanced HCC t
133 c antibody in combination with standard-dose systemic chemotherapy in the treatment of indolent B-cel
134  be beneficial for monitoring the success of systemic chemotherapy in the treatment of various tubero
135 ions of this disease, as well as the role of systemic chemotherapy in treatment of unresectable disea
136 patients (75%) were treated with neoadjuvant systemic chemotherapy in whom 32 (36%) were considered t
137 in 17 eyes and as secondary treatment (after systemic chemotherapy) in 7 eyes.
138 esection with hepatic-arterial infusion plus systemic chemotherapy including bevacizumab (Bev).
139 FUDR plus dexamethasone (Dex) and concurrent systemic chemotherapy including oxaliplatin or irinoteca
140  Localized disease was treated with combined systemic chemotherapy, including rituximab and radiation
141  intrathecal methotrexate in addition to the systemic chemotherapy indicated above.
142 ectal cancer complete postoperative adjuvant systemic chemotherapy, irrespective of tumor downstaging
143       The RR of asymptomatic BM from SCLC to systemic chemotherapy is 27% and evidently lower than th
144 apy is usually FOLFOX, but HAI combined with systemic chemotherapy is also an option.
145       Adjuvant HAI-FUDR combined with modern systemic chemotherapy is independently associated with i
146 nasal, nonnasal, and disseminated lymphomas, systemic chemotherapy is indicated.
147 nt of the disease and understand response to systemic chemotherapy is limited with current imaging ap
148     However, there is general agreement that systemic chemotherapy is rarely an effective form of man
149                                              Systemic chemotherapy is the most effective treatment fo
150 posi's sarcoma (KS), but the current role of systemic chemotherapy is undefined.
151 AI group) and 54 (55%) had received "modern" systemic chemotherapy (IV group).
152 th an isolated CNS relapse were treated with systemic chemotherapy known to enter into the CSF and in
153 AIDS-related Kaposi's sarcoma (AIDS-KS) with systemic chemotherapy, less toxic therapies are needed.
154 ansitional-cell carcinoma (TCC) treated with systemic chemotherapy may be a consequence of pretreatme
155 trinsic resistance of melanoma metastases to systemic chemotherapy may be due, in part, to the cells'
156                                Treatment was systemic chemotherapy (mostly anthracycline-based chemot
157             For patients who received modern systemic chemotherapy (n = 1,442), the median OS was 67
158  plaque radiotherapy (n = 3) plus additional systemic chemotherapy (n = 2).
159  surgery (n=5), radiation therapy (n=4), and systemic chemotherapy (n=4).
160 unosuppression, use of rituximab (n=10), and systemic chemotherapy (n=7).
161 ients who received surgery and postoperative systemic chemotherapy, no significant differences were o
162 derwent surgical resection and postoperative systemic chemotherapy of curative intent.
163 ctreotide, interferon, and both arterial and systemic chemotherapy, of which only chemoembolisation i
164 was to evaluate the influence of neoadjuvant systemic chemotherapy on patients with colorectal carcin
165                      Trials on the effect of systemic chemotherapy on survival and recurrence in adul
166 dvanced RCC treated on 24 clinical trials of systemic chemotherapy or cytokine therapy were the subje
167 homa who had been treated with standard-dose systemic chemotherapy or local therapy only.
168 homa who had been treated with standard-dose systemic chemotherapy or local therapy only.
169 t of 15 HIV-1-infected individuals receiving systemic chemotherapy or subsequent autologous stem cell
170 those recurrent after surgery, radiotherapy, systemic chemotherapy, or topical chemotherapy) vs treat
171 , young patients were more likely to receive systemic chemotherapy, particularly multiagent regimens,
172      INTERPRETATION: Traditional neoadjuvant systemic chemotherapy plus dual HER2-targeted blockade (
173                   Patients were treated with systemic chemotherapy plus intraocular injections of rit
174 hosis or in noncirrhosis patients exposed to systemic chemotherapy prior to RE.
175 omen with breast cancer treated with primary systemic chemotherapy (PST) is unknown.
176 urothelial cancer who had received one prior systemic chemotherapy regimen for advanced disease and h
177                                        These systemic chemotherapy regimens can also be applied both
178                                              Systemic chemotherapy regimens, including consolidative
179                                              Systemic chemotherapy remains the mainstay of treatment;
180 led that survivors who had been treated with systemic chemotherapy scored significantly lower on over
181 led that survivors who had been treated with systemic chemotherapy scored significantly lower on the
182             P9934 was a prospective trial of systemic chemotherapy, second surgery, and conformal rad
183 eritoneal metastases, failure of neoadjuvant systemic chemotherapy should not constitute an absolute
184 chemotherapy include early administration of systemic chemotherapy, shrinkage of primary tumor, and p
185 domized EORTC 62961 phase-III trial, RHT and systemic chemotherapy significantly improved local progr
186                                      RHT and systemic chemotherapy significantly improved LPFS (56% v
187 traocular retinoblastomas after radiation or systemic chemotherapy than has been reported in the lite
188 ven via intrathecal route concomitantly with systemic chemotherapy that crosses the blood-brain barri
189 solated CNS relapse of ALL were treated with systemic chemotherapy that effectively penetrates into t
190                                       Before systemic chemotherapy, the genetic expression of TS (TSm
191 occurred in 9 of 40 (23%) patients receiving systemic chemotherapy; the most common of these effects
192 fin photodynamic therapy in combination with systemic chemotherapy therapies and oral corticosteroids
193 noma, no resection of the primary tumor, and systemic chemotherapy, this study investigated the incid
194                 We find that the delivery of systemic chemotherapy through a certain form of nano-car
195 d in association with concomitant multiagent systemic chemotherapy to children younger than 3 years w
196 the COX2 and YAP1 pathways concurrently with systemic chemotherapy to improve the clinical management
197 ples from patients that have been exposed to systemic chemotherapy to infer the genomic landscape of
198 ults in unnecessary spending associated with systemic chemotherapy treatment.
199       Minimizing nondefinitive operative and systemic chemotherapy treatments before definitive cytor
200 tance and toxicities often limit benefits of systemic chemotherapy used to treat metastatic sarcomas.
201  with Reese-Ellsworth eye groups 1, 2, or 3, systemic chemotherapy used with local ophthalmic therapi
202 floxuridine (HAI-FUDR) in addition to modern systemic chemotherapy using oxaliplatin or irinotecan re
203 glioblastoma, and the median number of prior systemic chemotherapies was one.
204                                              Systemic chemotherapy was administered every 2 weeks con
205 on, the combination of dl1520 infection with systemic chemotherapy was assessed in these tumor xenogr
206                  The response to neoadjuvant systemic chemotherapy was assessed on data from previous
207 of SIR-Spheres therapy with modified FOLFOX4 systemic chemotherapy was conducted in patients with ino
208 s of patients with isolated PVRL, the use of systemic chemotherapy was not proven to prevent CNSL and
209  until no further benefit could be achieved; systemic chemotherapy was sometimes used as a palliative
210                       Survivors treated with systemic chemotherapy were also more likely to score in
211 tween 1996 and 2005 and treated with primary systemic chemotherapy were included.
212 rty-four patients who had not received prior systemic chemotherapy were randomized to either arm of t
213 cer who had not been previously treated with systemic chemotherapy were recruited from 91 academic me
214  completeness of CRS and the use of adjuvant systemic chemotherapy were the only significant prognost
215  bladder has traditionally been treated with systemic chemotherapy, which is most often platinum-base
216 e but applicable to only a few patients, and systemic chemotherapy, which is of uncertain benefit but
217 , extended intrathecal therapy and intensive systemic chemotherapy will, in all likelihood, replace c
218 tumors of the gynecologic tract will require systemic chemotherapy with a platinum agent and etoposid
219                      Seven patients received systemic chemotherapy with CHOP (cyclophosphamide, doxor
220 entral nervous system lymphoma are employing systemic chemotherapy with drugs that penetrate the bloo
221                Several studies have examined systemic chemotherapy with FOLFIRINOX (leucovorin and fl
222 everal reports demonstrating the efficacy of systemic chemotherapy with local PTT.
223  been no definitive trial comparing adjuvant systemic chemotherapy with no treatment.
224 le disease, consideration should be given to systemic chemotherapy with or without a biologic agent o
225 ompare outcomes in patients receiving modern systemic chemotherapy with or without HAI-FUDR.
226 roaches based on the site of malignancy, but systemic chemotherapy with or without radiation plays a
227  with HAI floxuridine and dexamethasone plus systemic chemotherapy with oxaliplatin and irinotecan.
228                   Twelve months of intensive systemic chemotherapy with reduced dose cranial radiatio
229 tal radiation of 30 gray in conjunction with systemic chemotherapy with rituximab can achieve disease
230 re randomized trials should compare HAI plus systemic chemotherapy with systemic therapy alone to ass
231 tive breast cancer that replaces traditional systemic chemotherapy with targeted treatment.
232 dy isolated limb infusion with melphalan and systemic chemotherapy with temozolomide.
233                                              Systemic chemotherapy with vincristine sulfate, etoposid
234 tched with 41 patients operated on following systemic chemotherapy without bevacizumab (bev-).

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top